Candel Therapeutics, Inc. — Director's Dealing 2021

Jul 27, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2021-07-26

Reporting Person: Meirav Udi (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	48822	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.46	2028-08-17	Common Stock (12205)		Direct
Stock Option (Right to Buy)	$1.46	2029-06-18	Common Stock (71198)		Direct
Stock Option (Right to Buy)	$1.55	2030-12-14	Common Stock (16274)		Direct
Stock Option (Right to Buy)	$6.64	2031-06-23	Common Stock (16274)		Direct

Footnotes

F1: 25% of this option vested and became exercisable on January 1, 2019, with the remainder vesting in three substantially equal monthly installments thereafter.

F2: This option is fully vested and exercisable as of the date hereof.